Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    0.00 (0.00%)
Bid:
1,015.00
Ask:
1,203.00
Spread: 188.00 (18.522%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

7 Jan 2010 07:00

RNS Number : 1561F
Persimmon PLC
07 January 2010
 



TRADING UPDATE - 7 JANUARY 2010

Persimmon plc announces the following update ahead of its Preliminary Results for the year ended 31 December 2009, which will be released on Tuesday 2 March 2010.

During the 12 month period to 31 December 2009 we have legally completed the sale of 8,976 new homes generating a turnover of c. £1.4 billion. Of these completions, 4,970 were achieved in the second half of 2009, an increase on the 4,006 completions achieved in the first half of 2009.

Since April 2008 the market has been very challenging. During this time we have concentrated on cash generation. By doing so, we have achieved a significant reduction in debt from £1.2 billion at April 2008 to c. £270 million at 31 December 2009 (31 December 2008: £599 million). This has been achieved by focusing closely on working capital management and strict cash control disciplines.

However we have also continued to invest in both work in progress on new and existing developments and new land acquisitions, where we have identified good opportunities at attractive margins.  We have acquired and agreed terms to acquire c. 3,000 plots during the latter months of 2009.  Of these plots over 80% are in southern markets.  Our land bank at the year end consisted of c. 61,000 plots.

In our Interim Management Statement on 16 November 2009 we commented that we had recently reserved the 1000th Persimmon home under the Government's HomeBuy Direct Scheme. We still have c. £45 million to utilise under this successful scheme from existing allocations to assist the sale of up to an additional c. 2,500 new homes.

We are therefore pleased to have received confirmation from the Homes & Communities Agency that our recent bid for funding under Kickstart 2 has been successful. We have been allocated an additional c. £50 million specifically to support potential purchasers of Persimmon homes under the HomeBuy Direct process. This will provide assistance to many first time buyers for c. 3,000 homes on c. 40 Persimmon developments across England between now and 2012.

We are currently operating from c. 370 developments throughout mainland  UK offering a wide range of family houses. This emphasis on more traditional housing is of great benefit to our business. Forward sales into 2010 are c. 40% ahead of last year at c. £640 million. This gives us a good start to the year, although as usual we await the Spring selling season with keen interest.

Whilst we will remain cautious until mortgage availability and the general economy improves, we have continued confidence in the long term future of the UK housing market.

On Tuesday 2 March 2010 details of the Group's performance for 2009 and a general market update will be provided with the announcement of our Results for the year ended 31 December 2009.

Mike Farley and Mike Killoran will host a conference call with analysts at 9:00am today. To participate please dial +44 (0203 037 9221. The password is 'Persimmon'.

For further information, please contact:

Edward Orlebar

Charlotte McMullen

Marylène Guernier

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

Persimmon plc

M:Communications

Tel: +44 (0) 1904 642199

Tel: +44 (0) 20 7920 2333


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBFMRTMBAMBLM
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.